Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Interest & Investment Income (2020 - 2025)

C4 Therapeutics (CCCC) has 6 years of Interest & Investment Income data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 14.91% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $10.3 million, down 28.28%, while the annual FY2025 figure was $10.3 million, 28.28% down from the prior year.
  • Interest & Investment Income reached $2.8 million in Q4 2025 per CCCC's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.9 million in Q1 2024 and bottomed at $69000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $1.9 million, with a median of $2.2 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 72.2% in 2021, then skyrocketed 1156.62% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $136000.0 in 2021, then surged by 1156.62% to $1.7 million in 2022, then skyrocketed by 72.62% to $2.9 million in 2023, then increased by 10.75% to $3.3 million in 2024, then dropped by 14.91% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $2.8 million in Q4 2025, $2.2 million in Q3 2025, and $2.5 million in Q2 2025.